The new arrangement, details of which were shared with plan holders earlier this month, affects around 260 medications under the insurance company's Specialty Drug Care program.
(note, Title copied from Global’s Twitter post on the article, which more clearly explains the concern, unlike the Headline).
It is not quite as sketchy as it sounds, but it’s still bad.
The medications in question are specially medications such as biologics that have unusual requirements like needing to be administered via infusion in a clinic by a nurse, or ultra expensive medications that are 10,000$+ per dose. Stuff you wouldn’t normally be able to stock at your corner pharmacy.
But still, patients should have the right to choose where they get their medication.
You are not logged in. However you can subscribe from another Fediverse account, for example Lemmy or Mastodon. To do this, paste the following into the search field of your instance: !canada@lemmy.ca
It is not quite as sketchy as it sounds, but it’s still bad.
The medications in question are specially medications such as biologics that have unusual requirements like needing to be administered via infusion in a clinic by a nurse, or ultra expensive medications that are 10,000$+ per dose. Stuff you wouldn’t normally be able to stock at your corner pharmacy.
But still, patients should have the right to choose where they get their medication.